4 results
The primary objective of this study is to determine the ability of reslizumab (110 mg) administered subcutaneously (sc) once every 4 weeks to produce a corticosteroid-sparing effect (as demonstrated by percent reduction in daily OCS use) in patients…
To test if IABP therapy is useful in patients presenting with large acute myocardial infarction complicated by persistent ischemia (no-reflow).
The primary objective of this study is to determine whether reslizumab, at a dosage of 0.3 or 3.0 mg/kg administered once every 4 weeks for a total of 4 doses, is more effective than placebo in improving lung function in patients with eosinophilic…
1. Evaluate safety and clinical and angiographic efficacy of BTK revascularization with IN.PACT Amphirion* randomized to standard, uncoated PTA balloons2. Assess the clinical efficacy of BTK revascularization with IN.PACT Amphirion* compared to a…